Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis

被引：36

作者：

Wen, Shu'an ^{[1
]}

Jing, Wei ^{[2
]}

Zhang, Tingting ^{[1
]}

Zong, Zhaojing ^{[1
]}

Xue, Yi ^{[1
]}

Shang, Yuanyuan ^{[1
]}

Wang, Fen ^{[1
]}

Huang, Hairong ^{[1
]}

Chu, Naihui ^{[2
]}

Pang, Yu ^{[1
]}

机构：

[1] Capital Med Univ, Beijing TB & Thorac Tumor Inst, Beijing Key Lab Drug Resistant TB Res, Natl Clin Lab TB,Beijing Chest Hosp, Beijing, Peoples R China

[2] Capital Med Univ, Beijing TB & Thorac Tumor Inst, Beijing Chest Hosp, Dept TB, Beijing, Peoples R China

来源：

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES | 2019年 / 38卷 / 07期

关键词：

Mycobacterium tuberculosis; Delamanid; Pretomanid; Susceptibility; Minimum inhibitory concentration;

D O I：

10.1007/s10096-019-03551-w

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Delamanid exhibited greater in vitro potency than pretomanid against multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB) isolates. The pretomanid minimum inhibitory concentration (MIC) values of four MDR-TB isolates were found to be resistant to delamanid ranging from 0.031 to 0.063mg/L. A novel nonsynonymous mutation within the fbiA gene (Glu249Lys) may be contributing to high-level resistance to delamanid and pretomanid in Mycobacterium tuberculosis.

引用

页码：1293 / 1296

页数：4

共 10 条

[1]

Denny WA, 2010, FUTURE MED CHEM, V2, P1295, DOI [10.4155/fmc.10.207, 10.4155/FMC.10.207]

[2] Mutations in Genes for the F420 Biosynthetic Pathway and a Nitroreductase Enzyme Are the Primary Resistance Determinants in Spontaneous In Vitro-Selected PA-824-Resistant Mutants of Mycobacterium tuberculosis [J].

Haver, Hana L. ;

Chua, Adeline ;

Ghode, Pramila ;

Lakshminarayana, Suresh B. ;

Singhal, Amit ;

Mathema, Barun ;

Wintjens, Rene ;

Bifani, Pablo .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (09) :5316-5323

[3]

Lee SFK, 2019, CURR OPIN PULM MED

[4] Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB) [J].

Liu, Yongge ;

Matsumoto, Makoto ;

Ishida, Hidekaza ;

Ohguro, Kinue ;

Yoshitake, Masuhiro ;

Gupta, Rajesh ;

Geiter, Lawrence ;

Hafkin, Jeffrey .

TUBERCULOSIS, 2018, 111 :20-30

[5]

Manjunatha Ujjini, 2009, Commun Integr Biol, V2, P215

[6]

Pang Y., 2017, Antimicrob Agents Chemother, V61

[7]

Shi J., 2018, Antimicrob Agents Chemother, V62

[8] MIC of Delamanid (OPC-67683) against Mycobacterium tuberculosis Clinical Isolates and a Proposed Critical Concentration [J].

Stinson, Kelly ;

Kurepina, Natalia ;

Venter, Amour ;

Fujiwara, Mamoru ;

Kawasaki, Masanori ;

Timm, Juliano ;

Shashkina, Elena ;

Kreiswirth, Barry N. ;

Liu, Yongge ;

Matsumoto, Makoto ;

Geiter, Lawrence .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (06) :3316-3322

[9] A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis [J].

Stover, CK ;

Warrener, P ;

VanDevanter, DR ;

Sherman, DR ;

Arain, TM ;

Langhorne, MH ;

Anderson, SW ;

Towell, JA ;

Yuan, Y ;

McMurray, DN ;

Kreiswirth, BN ;

Barry, CE ;

Baker, WR .

NATURE, 2000, 405 (6789) :962-966

[10] In Vitro and In Vivo Activities of the Nitroimidazole TBA-354 against Mycobacterium tuberculosis [J].

Upton, A. M. ;

Cho, S. ;

Yang, T. J. ;

Kim, Y. ;

Wang, Y. ;

Lu, Y. ;

Wang, B. ;

Xu, J. ;

Mdluli, K. ;

Ma, Z. ;

Franzblau, S. G. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (01) :136-144

← 1 →